Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.
Ansén
Sascha
S
Department I of Internal Medicine, Center for Integrated Oncology Köln-Bonn, Max Planck Institute for Neurological Research, Köln, Germany.
Bangard
Christopher
C
Querings
Silvia
S
Gabler
Franziska
F
Scheffler
Matthias
M
Seidel
Daniela
D
Saal
Beate
B
Zander
Thomas
T
Nogová
Lucia
L
Töpelt
Karin
K
Markert
Eva
E
Stoelben
Erich
E
Ernestus
Karen
K
Thomas
Roman K
RK
Wolf
Jürgen
J
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D010006:Osteoblasts / Q000187:drug effects*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D015996:Survival Rate
D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors